MX2024001893A - Compuestos heterociclicos y metodos de uso. - Google Patents
Compuestos heterociclicos y metodos de uso.Info
- Publication number
- MX2024001893A MX2024001893A MX2024001893A MX2024001893A MX2024001893A MX 2024001893 A MX2024001893 A MX 2024001893A MX 2024001893 A MX2024001893 A MX 2024001893A MX 2024001893 A MX2024001893 A MX 2024001893A MX 2024001893 A MX2024001893 A MX 2024001893A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- methods
- heterocyclic compounds
- compositions
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163231543P | 2021-08-10 | 2021-08-10 | |
| US202163289579P | 2021-12-14 | 2021-12-14 | |
| PCT/US2022/039971 WO2023018812A1 (en) | 2021-08-10 | 2022-08-10 | Heterocyclic compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001893A true MX2024001893A (es) | 2024-02-29 |
Family
ID=85201014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001893A MX2024001893A (es) | 2021-08-10 | 2022-08-10 | Compuestos heterociclicos y metodos de uso. |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4384160A4 (https=) |
| JP (1) | JP2024532734A (https=) |
| AU (1) | AU2022325771A1 (https=) |
| CA (1) | CA3228310A1 (https=) |
| MX (1) | MX2024001893A (https=) |
| TW (1) | TW202330529A (https=) |
| WO (1) | WO2023018812A1 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| EP4436571A4 (en) * | 2021-11-24 | 2025-10-15 | Merck Sharp & Dohme Llc | SMALL MOLECULE INHIBITORS OF KRAS MUTATIONAL PROTEINS |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| CA3247639A1 (en) | 2022-05-06 | 2023-11-09 | PAQ Therapeutics Inc. | CHIMERAS TARGET KRAS-G12D PROTEOLYSIS |
| WO2023213269A1 (en) * | 2022-05-06 | 2023-11-09 | Zai Lab (Shanghai) Co., Ltd. | Amide-substituted heterocyclic compounds as kras g12d modulators and uses thereof |
| CR20240508A (es) | 2022-05-19 | 2024-12-20 | Genentech Inc | Compuestos aza-tetracíclicos de oxazepina y usos de los mismos |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| EP4540244A1 (en) * | 2022-06-15 | 2025-04-23 | Mirati Therapeutics, Inc. | Prodrugs of pan-kras inhibitors |
| EP4549439A1 (en) * | 2022-07-01 | 2025-05-07 | Suzhou Zelgen Biopharmaceutical Co., Ltd. | Substituted pyrimidine-fused ring inhibitor, method for preparing same, and use thereof |
| WO2024008068A1 (en) * | 2022-07-04 | 2024-01-11 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| WO2024012519A1 (zh) * | 2022-07-13 | 2024-01-18 | 北京华森英诺生物科技有限公司 | Pan-kras抑制剂 |
| WO2024041606A1 (zh) * | 2022-08-24 | 2024-02-29 | 泰励生物科技（上海）有限公司 | 具有抗kras突变肿瘤活性的化合物 |
| TW202430179A (zh) | 2022-11-21 | 2024-08-01 | 美商樹線生物科學公司 | 螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑 |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| CN121464140A (zh) | 2023-04-14 | 2026-02-03 | 锐新医药公司 | Ras抑制剂的结晶形式、含有其的组合物及其使用方法 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025038936A1 (en) | 2023-08-17 | 2025-02-20 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| CN121941690A (zh) | 2023-10-03 | 2026-04-28 | Paq医疗公司 | Kras蛋白水解靶向嵌合体 |
| TW202529804A (zh) | 2023-10-06 | 2025-08-01 | 美商安進公司 | 用於癌症治療的組合療法 |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AU2024361909A1 (en) | 2023-10-20 | 2026-03-26 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202602882A (zh) * | 2024-03-14 | 2026-01-16 | 美商安進公司 | 作為ｋｒａｓ調節劑的大環化合物及其用途 |
| WO2025194054A1 (en) * | 2024-03-14 | 2025-09-18 | Amgen Inc. | Spirocyclic compounds as modulators of kras and uses thereof |
| WO2025228384A1 (en) * | 2024-04-30 | 2025-11-06 | Hutchmed Limited | Antibody-drug conjugates and use thereof |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103588792B (zh) * | 2013-03-04 | 2016-03-23 | 中国科学院上海药物研究所 | 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途 |
| EP3908283A4 (en) * | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| MX2022002465A (es) * | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| JP2023553492A (ja) * | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| CN117222650A (zh) * | 2021-04-30 | 2023-12-12 | 劲方医药科技(上海)有限公司 | 吡啶或嘧啶并环类化合物，其制法与医药上的用途 |
| BR112023024906A2 (pt) * | 2021-05-28 | 2024-02-15 | Redx Pharma Plc | Compostos |
-
2022
- 2022-08-10 WO PCT/US2022/039971 patent/WO2023018812A1/en not_active Ceased
- 2022-08-10 EP EP22856568.5A patent/EP4384160A4/en active Pending
- 2022-08-10 MX MX2024001893A patent/MX2024001893A/es unknown
- 2022-08-10 TW TW111130111A patent/TW202330529A/zh unknown
- 2022-08-10 JP JP2024507879A patent/JP2024532734A/ja active Pending
- 2022-08-10 AU AU2022325771A patent/AU2022325771A1/en active Pending
- 2022-08-10 CA CA3228310A patent/CA3228310A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024532734A (ja) | 2024-09-10 |
| EP4384160A1 (en) | 2024-06-19 |
| TW202330529A (zh) | 2023-08-01 |
| AU2022325771A1 (en) | 2024-02-15 |
| CA3228310A1 (en) | 2023-02-16 |
| WO2023018812A1 (en) | 2023-02-16 |
| EP4384160A4 (en) | 2025-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024001893A (es) | Compuestos heterociclicos y metodos de uso. | |
| MX2023012726A (es) | Compuestos heterociclicos y metodos de uso. | |
| MX2024001824A (es) | Compuestos heterociclicos y metodos de uso. | |
| JOP20220142A1 (ar) | مثبطات kras g12c | |
| MX2025001680A (es) | Compuestos heterociclicos, composiciones de los mismos y metodos de tratamiento con ellos | |
| MX2025011447A (es) | Inhibidores de kras | |
| JOP20250246A1 (ar) | مثبطات kras | |
| MX2024005228A (es) | Inhibidores de la sustitución de glicina a cisteína en la posición 12 (g12c) en el homólogo del oncogén viral de sarcoma de rata kirsten (kras). | |
| PH12020551464A1 (en) | Cd73 inhibitors | |
| GEAP202616866A (en) | 2-azabicyclo[2.2.1]heptane kras inhibitors | |
| ZA202100485B (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
| MX2026003002A (es) | Inhibidores de kras | |
| EP4520328A3 (en) | Heterocyclic compounds as immunomodulators | |
| MX2020011907A (es) | Inhibidores de kras g12c para el tratamiento de cancer. | |
| PH12021553233A1 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| PH12018502227A1 (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| MX2024013838A (es) | Compuestos y usos de estos | |
| MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. | |
| GEAP202415883A (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| MX2020008678A (es) | Metodos de uso para derivados de benzotriazol trisustituidos. | |
| MX2025001982A (es) | Inhibidores de kif18a y usos de estos | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| WO2021030379A9 (en) | Bicyclic heteroaryl compounds useful as irak4 inhibitors | |
| PH12022550497A1 (en) | Perk inhibiting compounds | |
| SA522432710B1 (ar) | مركبات حلقية غير متجانسة على هيئة مثبطات نازع تشبّع دلتا-5 وطرق لاستخدامها |